Alaska Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• ATTR-CM: Concomitant Therapy and Vutrisiran Treatment Effect; New Disease Progression Framework
  Concomitant use of tafamidis or heart failure (HF) therapies did not modify the treatment benefit of vutrisiran on all-cause mortality and recurrent cardiovascular events, according to a HELIOS-B analysis recently published in JACC.
• Eagle’s Eye View: Can Extreme Heat Impact Blood Pressure?
  In this week’s View, Dr. Eagle looks at a recent JACC: Advances Viewpoint that examines the challenges associated with implementing revisions to the definition of first medical contact (FMC) introduced in the 2025 ACC/AHA ACS Guideline and its implications for NCDR data collection.
• Beyond the Tumor: Dyslipidemia Management in Patients With and Survivors of Cancer
  ASCVD prevention has historically targeted the general adult population, with survivors of cancer and patients with active cancer being underrepresented. Cancer and its therapies may increase cardiovascular (CV) risk and accelerate vascular disease through treatment-related dyslipidemia...
• ACCEL Lite: Antithrombotic Therapy After TAVI
  In this episode, Deepak L. Bhatt MD, MPH, MBA, FACC and Øyvind H. Lie, MD, PhD, MSc examine the results of “ACASA-TAVI: Antithrombotic therapy after TAVI”.
• Whole-Grain Intake Tied to Improved Cardiometabolic Risk Factors in Meta-Analysis
  Higher whole-grain intake was associated with improvements in multiple cardiometabolic risk factors in a meta-analysis of randomized trials published Sept. 15 in EHJ. The largest effects were generally seen at whole-grain intakes of about 60-100 g/day.